Biogen (BIIB) PT Lowered to $191 at Bernstein

Bernstein SocGen Group analyst William Pickering lowered the price target on Biogen (NASDAQ: BIIB) to $191.00 (from $197.00) while maintaining a Market Perform rating.

The analyst commented: "Expect in-line results, with focus squarely on Leqembi SC and the pipeline; We tweak our 4Q25 estimates ahead of this Friday’s print. Our updated revenue estimate of $2,210M is in line with consensus, while our EPS estimate of $1.68 is 1% below (Exhibit 1). For FY26 guidance, we expect LMSD revenue decline and LSD EPS growth (Exhibit 2). While these numbers are nothing to write home about, investors are beginning to turn their attention to several promising growth opportunities that we discuss below. We maintain our Market-Perform rating. At the risk of getting too cute, we’d like to wait until we’re a bit closer to Leqembi inflection… probably after 3Q26. We lower our PT to $191 based on lower EPS estimates with no change to our valuation methodology."

You May Also Be Interested In

• Datadog (DDOG) PT Raised to Street High $330 at Benchmark
• Tenet Healthcare (THC) Reiterated at Overweight by Cantor Fitzgerald
• Home Depot (HD) Reiterated at Hold by Stifel as Survey Provides Positive Results